Latest Insider Transactions at Willis Towers Watson PLC (WTW)
This section provides a real-time view of insider transactions for Willis Towers Watson PLC (WTW). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of WILLIS TOWERS WATSON PLC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of WILLIS TOWERS WATSON PLC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2022
|
Kristy D Banas Chief Human Resources Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
480
-20.3%
|
$108,960
$227.62 P/Share
|
|
Apr 01
2022
|
Kristy D Banas Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
480
+16.87%
|
-
|
|
Apr 01
2022
|
Imran Ahmed Qureshi Global Head of Geographies |
BUY
Grant, award, or other acquisition
|
Direct |
1,013
+34.92%
|
-
|
|
Apr 01
2022
|
Imran Ahmed Qureshi Global Head of Geographies |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,014
-53.68%
|
$230,178
$227.62 P/Share
|
|
Apr 01
2022
|
Imran Ahmed Qureshi Global Head of Geographies |
BUY
Exercise of conversion of derivative security
|
Direct |
1,014
+34.93%
|
-
|
|
Apr 01
2022
|
Gene H Wickes Head of Benefits Deliv & Admin |
BUY
Grant, award, or other acquisition
|
Direct |
1,026
+1.35%
|
-
|
|
Apr 01
2022
|
Anne Pullum Co-Head of Corporate Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
1,151
+7.33%
|
-
|
|
Apr 01
2022
|
Joseph Stephen Kurpis PAO and Controller |
BUY
Grant, award, or other acquisition
|
Direct |
105
+20.15%
|
-
|
|
Apr 01
2022
|
Andrew Jay Krasner Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,684
+9.86%
|
-
|
|
Apr 01
2022
|
Julie Jarecke Gebauer Pres.-Health, Wealth & Career |
BUY
Grant, award, or other acquisition
|
Direct |
1,197
+1.2%
|
-
|
|
Apr 01
2022
|
Julie Jarecke Gebauer Pres.-Health, Wealth & Career |
SELL
Open market or private sale
|
Direct |
1,400
-1.42%
|
$330,400
$236.88 P/Share
|
|
Apr 01
2022
|
Adam Garrard Head of Risk & Broking |
BUY
Grant, award, or other acquisition
|
Direct |
1,197
+7.86%
|
-
|
|
Apr 01
2022
|
Matthew Furman General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
931
+3.37%
|
-
|
|
Apr 01
2022
|
Anne Donovan Bodnar Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,013
+6.17%
|
-
|
|
Apr 01
2022
|
Carl Aaron Hess Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,632
+12.04%
|
-
|
|
Mar 01
2022
|
Julie Jarecke Gebauer Pres.-Health, Wealth & Career |
SELL
Open market or private sale
|
Direct |
1,400
-1.4%
|
$310,800
$222.3 P/Share
|
|
Feb 28
2022
|
Carl Aaron Hess Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,300
-6.86%
|
$722,700
$219.26 P/Share
|
|
Feb 28
2022
|
Carl Aaron Hess Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+6.42%
|
$363,000
$110.58 P/Share
|
|
Feb 25
2022
|
Carl Aaron Hess Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,300
-3.25%
|
$726,000
$220.91 P/Share
|
|
Feb 25
2022
|
Carl Aaron Hess Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+6.03%
|
$363,000
$110.58 P/Share
|
|
Feb 22
2022
|
Carl Aaron Hess Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
105
-0.22%
|
$23,625
$225.61 P/Share
|
|
Feb 22
2022
|
Carl Aaron Hess Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,525
+8.58%
|
-
|
|
Feb 22
2022
|
Anne Pullum Co-Head of Corporate Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
3,248
+19.52%
|
-
|
|
Feb 22
2022
|
Gene H Wickes Head of Benefits Deliv & Admin |
SELL
Payment of exercise price or tax liability
|
Direct |
113
-0.15%
|
$25,425
$225.61 P/Share
|
|
Feb 22
2022
|
Gene H Wickes Head of Benefits Deliv & Admin |
BUY
Grant, award, or other acquisition
|
Direct |
4,525
+5.75%
|
-
|
|
Feb 22
2022
|
Julie Jarecke Gebauer Pres.-Health, Wealth & Career |
SELL
Payment of exercise price or tax liability
|
Direct |
114
-0.11%
|
$25,650
$225.61 P/Share
|
|
Feb 22
2022
|
Julie Jarecke Gebauer Pres.-Health, Wealth & Career |
BUY
Grant, award, or other acquisition
|
Direct |
4,525
+4.33%
|
-
|
|
Feb 22
2022
|
Matthew Furman General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,480
+11.89%
|
-
|
|
Feb 22
2022
|
Adam Garrard Head of Risk & Broking |
BUY
Grant, award, or other acquisition
|
Direct |
3,274
+20.33%
|
-
|
|
Feb 22
2022
|
Anne Donovan Bodnar Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-0.57%
|
$18,450
$225.61 P/Share
|
|
Feb 22
2022
|
Anne Donovan Bodnar Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,958
+16.96%
|
-
|
|
Feb 22
2022
|
Anne Donovan Bodnar Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
2,000
-5.16%
|
$446,000
$223.9 P/Share
|
|
Feb 14
2022
|
Julie Jarecke Gebauer Pres.-Health, Wealth & Career |
SELL
Open market or private sale
|
Direct |
2,400
-2.45%
|
$528,000
$220.99 P/Share
|
|
Jan 03
2022
|
Michelle R Swanback Director |
BUY
Grant, award, or other acquisition
|
Direct |
283
+50.0%
|
-
|
|
Jan 03
2022
|
Michael P. Hammond Director |
BUY
Grant, award, or other acquisition
|
Direct |
283
+50.0%
|
-
|
|
Jan 03
2022
|
Inga K Beale Director |
BUY
Grant, award, or other acquisition
|
Direct |
283
+50.0%
|
-
|
|
Jan 03
2022
|
Victor F Ganzi Director |
BUY
Grant, award, or other acquisition
|
Direct |
265
+1.17%
|
-
|
|
Dec 31
2021
|
John J Haley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,012
-0.29%
|
$239,844
$237.49 P/Share
|
|
Dec 31
2021
|
John J Haley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,570
+0.72%
|
-
|
|
Dec 29
2021
|
Jaymin B Patel Director |
SELL
Payment of exercise price or tax liability
|
Direct |
291
-5.09%
|
$69,258
$238.72 P/Share
|
|
Dec 29
2021
|
John J Haley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,373
-4.98%
|
$4,372,774
$238.72 P/Share
|
|
Dec 29
2021
|
John J Haley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,688
+11.24%
|
-
|
|
Dec 03
2021
|
John J Haley Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
28,900
-69.04%
|
$6,675,900
$231.97 P/Share
|
|
Dec 03
2021
|
John J Haley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
102,409
-12.82%
|
$23,758,888
$232.85 P/Share
|
|
Dec 03
2021
|
John J Haley Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,235
+26.15%
|
$16,525,850
$110.58 P/Share
|
|
Nov 15
2021
|
Anne Pullum Co-Head of Corporate Dev. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
410
-3.88%
|
$94,300
$230.91 P/Share
|
|
Nov 15
2021
|
Anne Pullum Co-Head of Corporate Dev. |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
40
+0.38%
|
-
|
|
Nov 15
2021
|
Julie Jarecke Gebauer Pres.-Health, Wealth & Career |
SELL
Sale (or disposition) back to the issuer
|
Direct |
42,010
-16.22%
|
$9,620,290
$229.73 P/Share
|
|
Nov 15
2021
|
Julie Jarecke Gebauer Pres.-Health, Wealth & Career |
BUY
Exercise of conversion of derivative security
|
Direct |
42,010
+23.11%
|
$4,621,100
$110.58 P/Share
|
|
Nov 02
2021
|
Adam Garrard Head of Risk & Broking |
SELL
Open market or private sale
|
Direct |
110
-1.14%
|
$26,180
$238.53 P/Share
|